{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T04:27:42Z","timestamp":1788064062831,"version":"build-2784847793"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273269"],"award-info":[{"award-number":["81273269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601011"],"award-info":[{"award-number":["81601011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211075"],"award-info":[{"award-number":["BK20211075"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene\u2010related peptide (CGRP) signaling molecule, and anti\u2010CGRP medications are used to abort and prevent migraine attacks. Erenumab, a monoclonal antibody that targets the CGRP receptor, is the first migraine preventive medication approved by the US Food and Drug Administration. In the present study, we evaluate the efficacy and safety of erenumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to systematically assess the efficacy and safety of erenumab as a migraine preventive treatment compared to a placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Randomized, placebo\u2010controlled, single or double\u2010blind trials were searched through MEDLINE, Embase, Cochrane Library, and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      up to May 2022. The efficacy outcomes we collected include changes from baseline on monthly migraine days, monthly acute migraine\u2010specific medication days, \u226550% responder rate, \u226575% responder rate, and 100% responder rate at week 12. Safety outcomes include treatment emergent adverse events, serious adverse events, and any adverse event that leads to discontinuation of treatment. The study was registered with PROSPERO (Registry number: CRD42022338861).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      In all eight included trials, we found that erenumab (28, 70, and 140\u2009mg) is very effective and has a significantly greater reduction in baseline monthly migraine days (28\u2009mg: mean difference [MD]\u00a0=\u00a0\u22121.1, 95% confidence interval [CI]: \u22122.0 to \u22120.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.020; 70\u2009mg: MD\u00a0=\u00a0\u22121.4, 95% CI: \u22121.8 to \u22121.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a026%; 140\u2009mg: MD\u00a0=\u00a0\u22121.8, 95% CI: \u22122.1 to \u22121.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%) than placebo at week 12, especially with 140\u2009mg. Otherwise, we found that there were no statistical differences in the occurrence of adverse events (7\u00a0mg: risk ratio [RR]\u00a0=\u00a00.9, 95% CI: 0.7 to 1.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.570; 21\u2009mg: RR\u00a0=\u00a01.0, 95% CI: 0.8 to 1.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.730; 28\u2009mg: RR\u00a0=\u00a00.9, 95% CI: 0.7 to 1.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.340; 70\u2009mg: RR\u00a0=\u00a01.0, 95% CI: 0.9 to 1.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.230,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%; 140\u2009mg: RR\u00a0=\u00a01.0, 95% CI: 0.9 to 1.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.880,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a040%) between the erenumab and placebo groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our study, we found that erenumab, especially at the dose of 140\u2009mg, is an effective and well\u2010tolerated preventive treatment for migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14423","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T07:07:22Z","timestamp":1668409642000},"page":"1281-1292","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta\u2010analysis of the efficacy and safety of randomized controlled trials"],"prefix":"10.1111","volume":"62","author":[{"given":"Tiantian","family":"Gui","sequence":"first","affiliation":[{"name":"Department of Neurology the First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology the First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology the First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology the First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology the First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7324-7982","authenticated-orcid":false,"given":"Qun","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Neurology the First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30293-9"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705806"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13081"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0524-7"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000837"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13379"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01633-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0944-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13652"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211024160"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","unstructured":"WangSJ.Efficacy and safety of erenumab 70 mg in adult patients with chronic migraine: results from a phase3 randomized double\u2010blind placebo\u2010controlled DRAGON study. AAN 2022 \u2013 74th Annual Meeting of the American Academy of Neurology (AAN);2022.","DOI":"10.1212\/WNL.98.18_supplement.2527"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30299-5"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14138"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01069-1"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666210823104916"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:08:28Z","timestamp":1762078108000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/head.14423"],"URL":"https:\/\/doi.org\/10.1111\/head.14423","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2022-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}